A double-blind cross-over study of ketoprofen (Orudis) 150 mg daily and ibuprofen (Brufen) 1,200 mg daily was carried out in 35 outpatients with rheumatoid arthritis. Results suggest that analgesic and anti-inflammatory activity of ketoprofen is superior to that of ibuprofen. Significantly greater pain relief (P < 0 05) and reduction in joint circumference (P <0-01) was obtained with ketoprofen than with ibuprofen. Side effects of the drugs were comparable and pot serious.
Introduction
Ketoprofen (Orudis), 2-(3-benzoylphenyl) propionic acid, is a new non-steroidal analgesic and anti-inflammatory agent, with a structure that bears a superficial similarity to the anti-inflammatory agent ibuprofen (Brufen) , in that it has a P-phenylpropionic group.
It has been shown to have potent analgesic, anti-inflammatory, and antibradykinin activities in studies in laboratory animals (Julou et al., 1971) .
Recent clinical studies have shown that ketoprofen is well tolerated by patients and has a low incidence of adverse reactions (G. Gomez, personal communication, 1972 ; D. W. Zutshi and R. M. Mason, personal communication, 1972) .
In double-blind cross-over studies ketoprofen has been found to have significant analgesic and anti-inflammatory activity compared with placebo (Cathcart et al., 1973; Zutshi et al., 1973) , and to have comparable therapeutic efficacy with indomethacin when given in equal dosage (Gyory et al., 1972) in patients with rheumatoid arthritis and osteoarthrosis of the hip.
Ibuprofen has been claimed as a useful analgesic and antiinflammatory agent; it is significantly less potent than indomethacin but has a lower incidence of side effects (OwenSmith and Burry, 1972; Hart, 1972 Objective assessments were of (a) grip strength-taken as the maximum of three readings made with each hand, and measured with a grip dynamometer attached to a sphygmomanometer and inflated to 30 mm Hg; (b) Joint circumference-at the initial assessment the two proximal interphalangeal joints showing most signs of inflammation were chosen. These were measured on each occasion, using the Geigy instrument, and the mean of two readings for each joint was taken; and (c) E.S.R., which was Cromie (1963) pointed out that gross alterations in formulations of trial drugs could possibly alter bioavailability, and theoretically the change in presentation of ibuprofen in the present study might have affected its bioavailability and reduced its effectiveness. However, the manufacturers (Boots) thought that the 200 mg capsules of ibuprofen used in this study were suitable for clinical trial purposes.
The results suggest that ketoprofen has analgesic and antiinflammatory activity superior to ibuprofen. It is noted particularly that statistically significant differences in activity, favouring ketoprofen, were obtained even with the comparatively small number of patients used in this study. These results are consistent with those of Owen-Smith and Burry (1972) and Gyory et al. (1972) , who showed, respectively, indomethacin 75 mg to have greater activity than ibuprofen 1,200 mg, and ketoprofen 100 mg to have comparable activity with indomethacin 100 mg. Cardoe (1969) and Goldberg et al. (1971) reported an overall reduction in E.S.R. in patients with rheumatoid arthritis treated with ibuprofen. The reduction in E.S.R. in the present study favoured ibuprofen (P < 0 05), despite the reverse finding for joint circumference.
A factor influencing the therapeutic efficacy of drugs, both in clinical trials and in other clinical situations, is drug interaction. Ketoprofen has been shown to have no effect on hepatic drugmetabolizing enzymes, based on a study of plasma-clearance of antipyrine (Cathcart et al., 1973) , and is unlikely therefore to interact with drugs metabolized by the liver.
An important consideration in assessing the value of a new drug for treatment of rheumatoid arthritis is incidence of adverse reactions. A drawback to the use of indomethacin, a powerful analgesic and anti-inflammatory agent, is a relatively high incidence of side effects. Ibuprofen has been found to be better tolerated, but its therapeutic efficacy has been questioned (Hart, 1972; Owen-Smith and Burry, 1972 (Robertson, 1965 (Robertson, , 1968 
